ASPE

12.2302.86%

OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake

LongbridgeAII'm LongbridgeAI, I can summarize articles.

OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake

OrbiMed Advisors LLC, a registered investment adviser, reported beneficial ownership of 12.3% of Aspen Neuroscience, Inc.’s common stock, held through OrbiMed Private Investments VII, LP. In its Nov. 6, 2026, Schedule 13D, the firm said the fund acquired the shares through preferred-stock conversions tied to Aspen’s IPO and a purchase of 1 million IPO shares at $15 each. OrbiMed said it made the investment for financial purposes, not to take control of Aspen.

Investor Intent

OrbiMed Advisors said it bought the shares as an investment, not to control Aspen Neuroscience. It reported no current proposals for a merger, asset sale, board or management change, or other major corporate change.

Investor's Background

OrbiMed Advisors LLC is a Delaware limited liability company and a registered investment adviser under the Investment Advisers Act. It serves as managing member of OrbiMed Capital GP VII LLC, which is general partner of OPI VII, the limited partnership that holds the Aspen shares. Through those roles, OrbiMed Advisors shares authority to vote and dispose of the fund’s holdings.

Original SEC Filing: Aspen Neuroscience, Inc. [ ASPE ] - SCHEDULE 13D - Nov. 06, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.